Valuation: Brii Biosciences Limited

Market Cap 530M 621M 79.11M 70.29M 65.6M 59.8M 113M 7.61B 114M 794M 308M 3.89B 297M 291M 12.48B P/E 2024
-1.32x
P/E 2025 -4.11x
Enterprise Value -1.4B -1.64B -209M -186M -173M -158M -298M -20.08B -300M -2.1B -812M -10.26B -784M -767M -32.94B EV / Sales 2024
-32.4x
EV / Sales 2025 -28.6x
Free-Float
93.29%
Yield 2024 *
-
Yield 2025 -
1 day-0.58%
1 week-3.37%
Current month-0.58%
1 month-5.49%
3 months-25.22%
6 months-39.44%
Current year-39.01%
1 week 0.85
Extreme 0.85
0.9
1 month 0.83
Extreme 0.83
0.94
Current year 0.83
Extreme 0.83
1.7
1 year 0.83
Extreme 0.83
2.34
3 years 0.8
Extreme 0.8
3.5
5 years 0.8
Extreme 0.8
48.65
10 years 0.8
Extreme 0.8
52.6
Manager TitleAgeSince
Chief Executive Officer 62 2018-02-22
Director of Finance/CFO 48 2020-08-31
Chief Tech/Sci/R&D Officer - 2024-01-02
Director TitleAgeSince
Chairman 62 2021-03-23
Director/Board Member 83 2021-06-21
Director/Board Member 66 2021-06-21
Date Insider Type Main position Quantity % Market Cap. Importance
9/21/26 Other

Chief Executive Officer

-24,172 0.0033%
8/27/26 Other

Chief Financial Officer

-1,500 0.0002%
10/30/25 Other

Chief Executive Officer

50,225 0.0069%
Change 5-day change 1-year change 3-year change Capi.($)
-0.58%-3.37%-60.19%-63.56% 79.11M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.26%-0.87%+41.35%+109.33% 39.06B
Weighted average by Cap. +0.12%-0.84%+56.93%+138.22%

Financials

2024 2025
Net sales 49.94M 58.44M 7.45M 6.62M 6.18M 5.63M 10.62M 716M 10.72M 74.74M 28.96M 366M 27.96M 27.36M 1.17B 35.55M 41.6M 5.3M 4.71M 4.4M 4.01M 7.56M 510M 7.63M 53.21M 20.62M 261M 19.91M 19.47M 836M
Net income -508M -595M -75.79M -67.34M -62.85M -57.29M -108M -7.29B -109M -761M -295M -3.72B -285M -278M -11.95B -223M -261M -33.2M -29.5M -27.53M -25.1M -47.33M -3.19B -47.77M -333M -129M -1.63B -125M -122M -5.24B
Net Debt -2.29B -2.68B -342M -304M -284M -258M -487M -32.87B -492M -3.43B -1.33B -16.8B -1.28B -1.26B -53.92B -1.93B -2.26B -288M -256M -239M -218M -410M -27.68B -414M -2.89B -1.12B -14.15B -1.08B -1.06B -45.41B
Logo Brii Biosciences Limited
Brii Biosciences Ltd is a biotechnology company primarily engaged in the development of therapies for infectious diseases and central nervous system diseases. The Company's main products include BRII-179, a candidate drug for hepatitis B virus (HBV) immunotherapy, Tobevibart, an investigational neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg), as well as soralimixin (BRII-693), a synthetic lipopeptide for treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacterial infections. The Company primarily operates its businesses in the domestic market.
Employees
80
Date Price Change Volume
26-10-02 HK$0.8600 -0.58% 121,500
26-09-30 HK$0.8650 +0.58% 396,500
26-09-29 HK$0.8600 -2.27% 257,500
26-09-28 HK$0.8800 -1.12% 293,000
26-09-25 HK$0.8900 0.00% 140,000
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2137 Stock